After surveying 35 physicians who treat pulmonary hypertension, JPMorgan analyst Jessica Fye remains cautious on shares of United Therapeutics (UTHR). The survey showed physicians expect oral prostacyclin use to drive overall prostacyclin category growth but that Johnson & Johnson's (JNJ) Uptravi will remain the preferred oral agent over United Therapeutics' Orenitram. Even with the stock pulling back 27% from the February highs, Fye does not see enough reasons to get more constructive on United Therapeutics. She keeps a Neutral rating on the name with a $125 price target.